Page 24 - Anales_81_1_2015
P. 24
P. Carmona et al
2005; 36: 307-19.
16. Selkoe DJ. Normal and abnormal biology of the beta-
amyloid precursor protein. Annu. Rev. Neurosci.1994;
17: 489–517.
17. Biere AL, Ostaszewski B, Stimson ER, et al. Amyloid
beta-peptide is transported on lipoproteins and
albumin in human plasma. J. Biol. Chem. 1996; 271:
32916–22.
18. Maler JM, Klafki HW, Paul S, et al. Urea-based two-
dimensional electrophoresis of beta-amyloid peptides
in human plasma: evidence for novel Abeta species.
Proteomics 2007; 7: 3815–20.
19. Zlokovic BV. Clearing amyloid through the blood–
brain barrier. J Neurochem 2004; 89: 807–11.
20. Chen M, Inestrosa NC, Ross GS, et al. Platelets are the
primary source of amyloid beta-peptide in human
blood. Biochem Biophys Res Commun 1995; 213:
96–103.
21. Liao P, Yu L, Kuo CC, et al. Proteomics analysis of
plasma for potential biomarkers in the diagnosis of
Alzheimer's disease. Proteomics. Clinical
Applications 2007; 1: 506–12.
22. Yu HL, Chertkow HM, Bergman H, et al. Aberrant
profiles of native and oxidized glycoproteins in
Alzheimer plasma. Proteomics 2003; 3: 2240–48.
23. Akiyama H, Barger S, Barnum, S, et al. Inflammation
and Alzheimer's disease. Neurobiol. Aging 2001; 21;
383–421.
24. Yasojima K, Schwab C, McGeer EG, et al. Human
neurons generate C-reactive protein and amyloid P:
upregulation in Alzheimer's disease. Brain Res 2000;
887: 80–9.
25. Frank RA, Galasko D, Hampel H, et al. Biological
markers for therapeutic trials in Alzheimer's disease.
Proceedings of the biological markers working group;
NIA initiative on neuroimaging in Alzheimer's
disease. Neurobiol. Aging 2003; 24: 521–36.
24 @Real Academia Nacional de Farmacia. Spain
2005; 36: 307-19.
16. Selkoe DJ. Normal and abnormal biology of the beta-
amyloid precursor protein. Annu. Rev. Neurosci.1994;
17: 489–517.
17. Biere AL, Ostaszewski B, Stimson ER, et al. Amyloid
beta-peptide is transported on lipoproteins and
albumin in human plasma. J. Biol. Chem. 1996; 271:
32916–22.
18. Maler JM, Klafki HW, Paul S, et al. Urea-based two-
dimensional electrophoresis of beta-amyloid peptides
in human plasma: evidence for novel Abeta species.
Proteomics 2007; 7: 3815–20.
19. Zlokovic BV. Clearing amyloid through the blood–
brain barrier. J Neurochem 2004; 89: 807–11.
20. Chen M, Inestrosa NC, Ross GS, et al. Platelets are the
primary source of amyloid beta-peptide in human
blood. Biochem Biophys Res Commun 1995; 213:
96–103.
21. Liao P, Yu L, Kuo CC, et al. Proteomics analysis of
plasma for potential biomarkers in the diagnosis of
Alzheimer's disease. Proteomics. Clinical
Applications 2007; 1: 506–12.
22. Yu HL, Chertkow HM, Bergman H, et al. Aberrant
profiles of native and oxidized glycoproteins in
Alzheimer plasma. Proteomics 2003; 3: 2240–48.
23. Akiyama H, Barger S, Barnum, S, et al. Inflammation
and Alzheimer's disease. Neurobiol. Aging 2001; 21;
383–421.
24. Yasojima K, Schwab C, McGeer EG, et al. Human
neurons generate C-reactive protein and amyloid P:
upregulation in Alzheimer's disease. Brain Res 2000;
887: 80–9.
25. Frank RA, Galasko D, Hampel H, et al. Biological
markers for therapeutic trials in Alzheimer's disease.
Proceedings of the biological markers working group;
NIA initiative on neuroimaging in Alzheimer's
disease. Neurobiol. Aging 2003; 24: 521–36.
24 @Real Academia Nacional de Farmacia. Spain
